The European Association of Urology (EAU) “Update on Prostate Cancer” meeting was held in Vienna, Austria, on Friday and Saturday, and Dr. Zachary Klaassen was again busy providing summary reports on presentations for UroToday. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: active surveillance, Diagnosis, PSA, screening, staging, testing | Leave a comment »
Two recent papers by Sabouri et al. have suggested that a new MRI techique known as “luminal water imaging” may be able to improve the ability of MR scans to identify and grade prostate cancer prior to biopsy. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Diagnosis, fraction, imaging, luminal, MRI, staging, water | 2 Comments »
The most recent, 8th edition, of the American Joint Committee on Cancer (AJCC) Staging Manual has introduced some relatively minor modifications to the standards for staging of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: AJCC, chnge, criteria, staging, standard | 2 Comments »
It is clear that modern magnetic resonance imaging is getting closer to being able to make a major difference to the way that we diagnose (and potentially manage) localized prostate cancer … always assuming we can afford the costs involved (at least here in the USA). … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: accuracy, Diagnosis, MRI, risk, staging | 2 Comments »
According to a report from a major British teaching hospital, simple, standard, 1.5 T MRI scanning (without use of an endorectal coil) does not improve preoperative staging of localized prostate cancer and should not be used in this scenario. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: MRI, pre-surgical, staging, standard | 7 Comments »
In recent years it has become increasingly widely accepted that clinical stage is of dubious value as a prognostic factor in determining prostate cancer risk, particularly as regards the sub-stages of clinical stage T2 (i.e., T2a, T2b, and T2c) in men with localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: biopsy, cores, localized, positive, PPC, staging | 10 Comments »
Among prostate cancer specialists, there has been a broad acceptance — for some time — of the idea that a localized prostate cancer “index” tumor with a Gleason score of 6 or less and a volume of ≤ 0.5 cm3 could be considered to be clinically insignificant and therefore did not (necessarily) need to be treated. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: clinical insignificance, clinical significance, Gleason grade, Management, staging, tumor volume | Leave a comment »
The staging systems used by clinicians and pathologists for assignment of the stage of prostate cancer were all developed more than 20 years ago, and have seen only relatively minor adjustments since the introduction of the PSA test. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: clinical stage, Diagnosis, prognosis, relevance, staging | 2 Comments »
There are three pathological subclassifications of prostate cancer that is confined to the prostate: T2a disease (cancer confined to one half of either the left or right lobe or side of the prostate), T2b disease (cancer that is found throughout one lobe or side of the prostate) and T2c disease (cancer that is evident in both lobes or sides of the prostate). Historically, it has been considered that these stages of organ-confined prostate cancer are “different”with respect to risk for progression. However, new data suggests that this may not actually be the case. … READ MORE …
Filed under: Management | Tagged: staging | 1 Comment »
Another report from the Medical College of Georgia identifies a protein called β-arrestin 2 (or βarrestin2) as having lower levels in certain types of prostate cancer cells than in normal prostate cells, while expression of testosterone-stimulated androgen receptors is higher. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: Diagnosis, β-arrestin 2, βarrestin2, risk, staging | Leave a comment »
Four new reports today deal with:
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: Diagnosis, grade, LUTS, magnetic resonance, MRI, sorenafib, staging | Leave a comment »
We have separately addressed a report from Australia on the potential of PSA “signatures” as prognostic indicators of prostate cancer progression. In other news today: … READ MORE …
Filed under: Diagnosis, Management | Tagged: Diagnosis, endoglin, imaging, PCA3, staging | Leave a comment »
Articles summarized in this weekend news update include information about:
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cancer, endorectal, imaging, prostate, PSA, PSA velocity, replacement, salvage, staging, survival, testosterone | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 